6ehy
From Proteopedia
(Difference between revisions)
m (Protected "6ehy" [edit=sysop:move=sysop]) |
|||
| (2 intermediate revisions not shown.) | |||
| Line 1: | Line 1: | ||
| - | '''Unreleased structure''' | ||
| - | + | ==scFv AbVance: increasing our knowledge of antibody structural space to enable faster and better decision making in drug discovery== | |
| + | <StructureSection load='6ehy' size='340' side='right'caption='[[6ehy]], [[Resolution|resolution]] 2.25Å' scene=''> | ||
| + | == Structural highlights == | ||
| + | <table><tr><td colspan='2'>[[6ehy]] is a 2 chain structure with sequence from [https://en.wikipedia.org/wiki/Homo_sapiens Homo sapiens]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=6EHY OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=6EHY FirstGlance]. <br> | ||
| + | </td></tr><tr id='method'><td class="sblockLbl"><b>[[Empirical_models|Method:]]</b></td><td class="sblockDat" id="methodDat">X-ray diffraction, [[Resolution|Resolution]] 2.25Å</td></tr> | ||
| + | <tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=6ehy FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=6ehy OCA], [https://pdbe.org/6ehy PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=6ehy RCSB], [https://www.ebi.ac.uk/pdbsum/6ehy PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=6ehy ProSAT]</span></td></tr> | ||
| + | </table> | ||
| - | + | ==See Also== | |
| - | + | *[[Antibody 3D structures|Antibody 3D structures]] | |
| - | + | *[[Monoclonal Antibodies 3D structures|Monoclonal Antibodies 3D structures]] | |
| - | [[Category: | + | *[[3D structures of human antibody|3D structures of human antibody]] |
| - | [[Category: Hargreaves | + | __TOC__ |
| + | </StructureSection> | ||
| + | [[Category: Homo sapiens]] | ||
| + | [[Category: Large Structures]] | ||
| + | [[Category: Hargreaves D]] | ||
Current revision
scFv AbVance: increasing our knowledge of antibody structural space to enable faster and better decision making in drug discovery
| |||||||||||
